Author: Abu Jawdeh, Bassam G.
Title: COVID-19 in Kidney Transplantation: Outcomes, Immunosuppression Management and Operational Challenges Cord-id: 0w0pjjg1 Document date: 2020_7_17
ID: 0w0pjjg1
Snippet: Abstract The Coronavirus disease 2019 (COVID-19) pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus 2, has led to the death of hundreds of thousands of people worldwide. If infected, older individuals and those with diabetes, hypertension, cardiovascular disease and compromised immune systems are at higher risk for unfavorable outcomes. These comorbidities are prevalent in patients with kidney disease, hence the significant burden of COVID-19 on kidney transplant programs. Mul
Document: Abstract The Coronavirus disease 2019 (COVID-19) pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus 2, has led to the death of hundreds of thousands of people worldwide. If infected, older individuals and those with diabetes, hypertension, cardiovascular disease and compromised immune systems are at higher risk for unfavorable outcomes. These comorbidities are prevalent in patients with kidney disease, hence the significant burden of COVID-19 on kidney transplant programs. Multiple case series of kidney transplant recipients with COVID-19 have shown increased mortality compared to non-transplant patients. To-date, we do not have high-level evidence to inform immunosuppression minimization strategies in infected transplant recipients. Most centers however have adopted early anti-metabolite withdrawal in addition to other interventions. This review summarizes the published COVID-19 literature as it relates to outcomes and immunosuppression management in kidney transplant recipients. It also discusses challenges pertaining to pre-transplant evaluation and wait-listed patients.
Search related documents:
Co phrase search for related documents- acid testing and liver injury: 1
- acid testing and lopinavir ritonavir: 1, 2, 3, 4
- acid testing and low threshold: 1
- acute aki kidney injury and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- acute aki kidney injury and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8
- acute aki kidney injury and low threshold: 1
- acute respiratory and adjunctive medication: 1
- acute respiratory and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and low dose glucocorticoid: 1, 2, 3
- acute respiratory and low threshold: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- liver injury and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- liver injury and low threshold: 1
- lopinavir ritonavir and low dose glucocorticoid: 1
Co phrase search for related documents, hyperlinks ordered by date